-
公开(公告)号：US20190161448A1
公开(公告)日：2019-05-30
申请号：US16096710
申请日：2017-05-19
Applicant: Merck Sharp & Dohme Corp.
Inventor： Gregory L. Adams , Jason M. Cox , John S. Debenham , Scott Edmondson , Eric J. Gilbert , Yan Guo , Yu Jiang , Hubert Josien , Hyunjin M. Kim , Ping Lan , Shouwu Miao , Christopher W. Plummer , Murali Rajagopalan , Unmesh Shah , Zhongxiang Sun , Quang T. Truong , Feroze Ujjainwalla , Francisco Velazquez , Srikanth Venkatraman , Takao Suzuki , Nengxue Wang
IPC: C07D217/04 , C07D401/12 , C07D401/04 , C07D401/06 , C07D417/04 , C07D417/14 , C07D417/12 , C07D413/04 , A61P3/10 , A61P3/06 , A61P3/04 , A61P29/00
Abstract: The present invention relates to a compound represented by formula (I) and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.
-
Patent Agency Ranking
公开(公告)号：US09868727B2
公开(公告)日：2018-01-16
申请号：US15329634
申请日：2015-07-23
Applicant: Merck Sharp & Dohme Corp.
Inventor： Weiguo Liu , Scott D. Edmondson , Zhuyan Guo , Sung-Sau So , Anthony K. Ogawa , Rongze Kuang , Heping Wu , Amjad Ali , Ying-Duo Gao , Yu Jiang , Chunsing Li , Tingting Yu
IPC: C07D409/14 , C07D417/14 , C07D413/14 , C07D401/14 , C07D401/06 , A61K31/4439 , A61K31/444
CPC classification number: C07D409/14 , A61P7/02 , C07D401/06 , C07D401/14 , C07D413/14 , C07D417/14
Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
-
公开(公告)号：US20170210732A1
公开(公告)日：2017-07-27
申请号：US15329634
申请日：2015-07-23
Applicant: Merck Sharp & Dohme Corp.
Inventor： Weiguo Liu , Scott D. Edmondson , Zhuyan Guo , Sung-Sau So , Anthony K. Ogawa , Rongze Kuang , Heping Wu , Amjad Ali , Ying-Duo Gao , Yu Jiang , Chunsing Li , Tingting Yu
IPC: C07D409/14 , C07D401/06 , C07D401/14 , C07D417/14 , C07D413/14
CPC classification number: C07D409/14 , A61P7/02 , C07D401/06 , C07D401/14 , C07D413/14 , C07D417/14
Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
-
公开(公告)号：US11161819B2
公开(公告)日：2021-11-02
申请号：US16935565
申请日：2020-07-22
Applicant: Merck Sharp & Dohme Corp.
Inventor： Gregory L. Adams , Jason M. Cox , John S. Debenham , Scott Edmondson , Eric J. Gilbert , Yan Guo , Yu Jiang , Hubert Josien , Hyunjin M. Kim , Ping Lan , Shouwu Miao , Christopher W. Plummer , Murali Rajagopalan , Unmesh Shah , Zhongxiang Sun , Quang T. Truong , Feroze Ujjainwalla , Francisco Velazquez , Srikanth Venkatraman , Takao Suzuki , Nengxue Wang
IPC: C07D217/04 , C07D401/04 , C07D401/12 , C07D413/04 , C07D417/12 , C07D417/14 , C07D401/06 , C07D417/04 , A61K31/4725 , C07D417/06 , C07D217/22 , A61K45/06 , A61K31/472 , A61K9/48 , A61P3/04 , A61P3/06 , A61P3/10 , A61P29/00
Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.
-
公开(公告)号：US20200347020A1
公开(公告)日：2020-11-05
申请号：US16935565
申请日：2020-07-22
Applicant: Merck Sharp & Dohme Corp.
Inventor： Gregory L. Adams , Jason M. Cox , John S. Debenham , Scott Edmondson , Eric J. Gilbert , Yan Guo , Yu Jiang , Hubert Josien , Hyunjin M. Kim , Ping Lan , Shouwu Miao , Christopher W. Plummer , Murali Rajagopalan , Unmesh Shah , Zhongxiang Sun , Quang T. Truong , Feroze Ujjainwalla , Francisco Velazquez , Srikanth Venkatraman , Takao Suzuki , Nengxue Wang
IPC: C07D217/04 , C07D401/04 , C07D401/12 , C07D413/04 , C07D417/12 , C07D417/14 , C07D401/06 , C07D417/04 , A61K31/4725 , C07D417/06 , C07D217/22 , A61K45/06 , A61K31/472 , A61K9/48 , A61P3/04 , A61P3/06 , A61P3/10 , A61P29/00
Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing diabetes, hyperlipidemia, obesity, NASH, inflammation related disorders, and related diseases and conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR120. Pharmaceutical compositions and methods of treatment are also included.
-
公开(公告)号：US10093683B2
公开(公告)日：2018-10-09
申请号：US15305421
申请日：2015-04-21
Applicant: Merck Sharp & Dohme Corp.
Inventor： Yeon-Hee Lim , Zhuyan Guo , Amjad Ali , Scott D. Edmondson , Weiguo Liu , Gioconda V. Gallo-Etienne , Heping Wu , Ying-Duo Gao , Andrew W. Stamford , Younong Yu , Nancy J. Kevin , Rajan Anand , Deyou Sha , Santhosh F. Neelamkavil , Zahid Hussain , Puneet Kumar , Remond Moningka , Joseph L. Duffy , Jiayi Xu , Yu Jiang , Anjan Chakrabarti , Hiroki Sone
IPC: C07D498/20 , C07F9/6561 , C07D487/10 , C07D498/10 , C07D471/10
Abstract: The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more compounds of Formula (I), and methods for using the compounds of Formula (I) for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.
-
-
-
-
-
Search Results
6
records
(took 0.02 seconds)
